Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Conditions
Rheumatoid Arthritis
Interventions
Teriparatide, calcium citrate, Vitamin D, TNF antagonist
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Conditions
Osteoporosis
Interventions
Parathyroid hormone (hPTH 1-34)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
San Francisco, California
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate Sodium, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
6
States / cities
Loma Linda, California • Palo Alto, California • Aurora, Colorado + 3 more
Conditions
Age-Related Osteoporosis
Interventions
Teriparatide, Alendronate
Drug
Lead sponsor
Madhumathi Rao
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Not applicable Interventional Accepts healthy volunteers Results available

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism

NCT00754442
Conditions
Secondary Hyperparathyroidism
Interventions
Teriparatide
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years to 59 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Osteoporosis
Interventions
Teriparatide (PF708), Teriparatide (Forteo)
Drug
Lead sponsor
Pfenex, Inc
Industry
Eligibility
30 Years to 85 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 22 more
Terminated Phase 2 Interventional Results available

Teriparatide for Postsurgical Hypoparathyroidism

NCT01171690
Conditions
Hypoparathyroidism Post-surgical
Interventions
Teriparatide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Phase 4 Interventional Results available

Novel Combination Therapy for Osteoporosis in Men

NCT03994172
Conditions
Male Osteoporosis
Interventions
Teriparatide or human parathyroid hormone (PTH) 1-34, Cinacalcet, placebo tablet, Calcium citrate tablet, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 85 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Completed Not applicable Interventional Results available

Renal Osteodystrophy: An Individual Management Approach

NCT02440581
Conditions
Kidney Failure, Chronic
Interventions
Alendronate, Teriparatide, Cinacalcet
Drug
Lead sponsor
Hartmut Malluche, MD
Other
Eligibility
21 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Phase 3 Interventional Results available

Effect of Teriparatide on Hip Fracture Healing

NCT01473589
Conditions
Femur Neck Fracture
Interventions
Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • La Mesa, California + 21 more
Conditions
Leukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis, Lymphoma, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, Leukemia, Myelocytic, Acute, Leukemia, Lymphocytic, Acute
Interventions
Parathyroid Hormone (teriparatide)
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Gainesville, Florida • Boston, Massachusetts
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?

NCT01166958
Conditions
Osteoporosis
Interventions
Teriparatide, Raloxifene
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 89 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Osteoporosis, Postmenopausal Osteoporosis
Interventions
Placebo, BA058 80 mcg, teriparatide
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
2,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • North Miami, Florida + 2 more
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D, Placebo-Oral, Placebo-SC
Drug · Dietary Supplement
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
15
States / cities
Mobile, Alabama • Tustin, California • Lakewood, Colorado + 12 more
Conditions
Osteoporosis
Interventions
zoledronic acid
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
Up to 85 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Osteopenia, Osteoporosis
Interventions
Teriparatide, Placebo teriparatide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bangor, Maine
Conditions
Adult Idiopathic Generalized Osteoporosis
Interventions
Denosumab
Drug
Lead sponsor
Elizabeth Shane
Other
Eligibility
20 Years to 50 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Omaha, Nebraska • New York, New York
Conditions
Osteoporosis
Interventions
Standard Clinical Practice Regimen, Experimental Cyclic Regimen
Drug
Lead sponsor
Health Research, Inc.
Other
Eligibility
45 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
West Haverstraw, New York
Conditions
Osteoporosis
Interventions
Teriparatide, Denosumab, Demeclocycline, Tetracycline, Calcium Supplement, Vitamin D
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 89 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Lakewood, Colorado • Gainesville, Georgia • Detroit, Michigan + 1 more
Not listed Phase 2 Interventional Accepts healthy volunteers

Cyclic Versus Daily Teriparatide on Bone Mass

NCT00668941
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
45 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
1
States / cities
West Haverstraw, New York
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

NCT01279187
Conditions
Implant
Interventions
Teriparatide, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Colles' Fracture
Interventions
Teriparatide, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years to 85 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Postmenopausal Osteoporosis
Interventions
teriparatide, aldrenodate, raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
10
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
Conditions
Osteoporosis, Postmenopausal
Interventions
teriparatide, Placebo, Calcium Supplement, Vitamin D Supplement
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years to 85 Years · Female only
Enrollment
1,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1999
U.S. locations
1
States / cities
Boston, Massachusetts